These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19098509)

  • 81. Smoking cessation: aspects of prevention and therapy. The activity of the Smoking Cessation Center of Parma-Italy.
    Mariano ME; Elia D; Scarascia A; Tzani P; Giucastro G; Olivieri D; Marangio E
    Acta Biomed; 2009 Apr; 80(1):42-6. PubMed ID: 19705619
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Smoking cessation pharmacotherapy.
    Frishman WH
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):287-308. PubMed ID: 19491139
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix).
    Zesiewicz TA; Sullivan KL; Gooch CL; Lynch DR
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):191-3. PubMed ID: 19494730
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Molecular and cellular mechanisms of action of nicotine in the CNS.
    Barik J; Wonnacott S
    Handb Exp Pharmacol; 2009; (192):173-207. PubMed ID: 19184650
    [TBL] [Abstract][Full Text] [Related]  

  • 85. alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?
    Paleari L; Cesario A; Fini M; Russo P
    Drug Discov Today; 2009 Sep; 14(17-18):822-36. PubMed ID: 19616116
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial.
    Shiffman S; Ferguson SG; Strahs KR
    Am J Prev Med; 2009 Feb; 36(2):96-104.e1. PubMed ID: 19135903
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Grover disease may result from the impairment of keratinocytic cholinergic receptors.
    Paslin D
    J Am Acad Dermatol; 2012 Feb; 66(2):332-3. PubMed ID: 22243730
    [No Abstract]   [Full Text] [Related]  

  • 88. Nicotinic acetylcholine receptors as therapeutic targets: emerging frontiers in basic research and clinical science - editorial comments.
    Gopalakrishnan M; Bertrand D; Williams M
    Biochem Pharmacol; 2007 Oct; 74(8):1091. PubMed ID: 17889037
    [No Abstract]   [Full Text] [Related]  

  • 89. Withdrawal-Emergent Dyskinesias following Varenicline Therapy.
    Toffey BA; Rabin M; Kurlan R
    Open Neurol J; 2015; 9():7-8. PubMed ID: 26106454
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Smoking cessation: an overview of treatment options with a focus on varenicline.
    Stack NM
    Pharmacotherapy; 2007 Nov; 27(11):1550-7. PubMed ID: 17963463
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
    Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
    J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Varenicline: the French experience after 6 months.
    Prescrire Int; 2009 Feb; 18(99):25. PubMed ID: 19396936
    [No Abstract]   [Full Text] [Related]  

  • 93. Varenicline (Chantix) warnings: risk versus benefit.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):53. PubMed ID: 18617873
    [No Abstract]   [Full Text] [Related]  

  • 94. Quitting smoking without a psychotic break: the potential link between nicotinic acetylcholine receptor partial agonists and neuropsychiatric adverse events.
    O'Malley P
    Clin Nurse Spec; 2009; 23(1):13-5. PubMed ID: 19098509
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.